Up to 70 percent of active pharmaceutical ingredients (APIs) in today’s drug pipeline are poorly soluble, which complicates delivery and results in poor bioavailability. Organic solvents, such as dimethyl sulfoxide (DMSO), are toxic and incompatible with clinical use.
Whether you need to contemporize a well-known but mature brand franchise, expand on an upcoming or recent Rx-to-OTC switch, or broaden the audience appeal of any OTC or VMS product, the strategic use of novel drug delivery systems can provide opportunities to grow a brand and increase sales.
About 90 percent of API molecules in the discovery pipeline are water insoluble, contributing to bioavailability challenges.
Parsolex is a contract development and manufacturing services organization (CDMO) that works with clients involved in the research, development, and commercialization of non-sterile pharmaceutical products. The company’s clients include small, large, and virtual pharmaceutical companies; research universities; clinical research organizations; and hospitals.
Some companies operating slat fillers try to use one set of slats for many different products. However, slats should generally be product specific.
Hard capsules are traditionally composed of pure gelatin and water and are available in a wide variety of shapes, sizes, and colors. Consumers find them easy to swallow, and industry prefers them because they protect sensitive drug formulations and offer a high level of API bioavailability.
For experts in lean manufacturing, batch processing is sub-optimal. One-piece flow represents the ideal—a widget created as the customer demands it, satisfying the customer, optimizing the company’s resources, and delivering higher quality in real time. In the pharmaceutical industry, batch manufacturing has long been standard practice.